drug
Developments in Myelofibrosis: Ongoing Trials and the Significance of Mutations
Mayo Clinic expert, Dr. Ruben Mesa provides an update from the 2012 American Society of Hematology Meeting on important news for patients living with Myelofibrosis. He talks about where we are in understanding myeloproliferative disorders and what genetic changes patients experience that could potentially predict the behavior of the disease.… Continue reading
The Promise of Better Treatments for Myelofibrosis
The landscape of care is changing for patients with myelofibrosis. A new drug, that experts say can significantly improve symptoms for many patients, has been recently approved while significant research is underway to better manage the progressive scarring in the bone marrow which is at the root of the condition.… Continue reading
The Promise of Better Treatments for Myelofibrosis
The landscape of care is changing for patients with myelofibrosis. A new drug, that experts say can significantly improve symptoms for many patients, has been recently approved while significant research is underway to better manage the progressive scarring in the bone marrow which is at the root of the condition.… Continue reading
Jakafi Makes Its Way To The UK
Myelofibrosis sufferers in the UK now have access to treatment following the launch of Jakavi, Novartis’ targeted drug therapy for the disease. This is great news as Jakafi has now been approved for use in the US, Canada, Europe and the UK. It will now be only a matter… Continue reading
Drug Extends Survival for Myelofibrosis Patients
A drug that relieves the severe symptoms of a life-threatening bone marrow cancer called myelofibrosis also improves the survival of patients with the disease, according to a phase III clinical trial published in the March 1 edition of New England Journal of Medicine. “The Phase I/II clinical trial showed that… Continue reading